Shares of MAP Pharmaceuticals, Inc. (Nasdaq:MAPP) are slightly higher on news after the close on Monday that a stage 2 clinical trial of a drug for the treatment of asthma and chronic obstructive pulmonary disease showed positive results.

“The results…demonstrate our ability to apply our proprietary technologies to combine two drugs within a single particle in a pre-specified ratio and deliver them to the lung,” CEO Timothy Nelson said in a statement.

At 2:29 p.m. ET, the stock had advanced $0.20, or 1%, to $13.70. For detailed price information and recent news stories about MAP Pharmaceuticals, click MAPP.